New pill targets Hard-to-Treat cancers with specific gene mutation
Disease control
Recruiting now
This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…
Phase: PHASE1, PHASE2 • Sponsor: Ensem Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC